Ray Matthews, MD
Interventional Cardiology · Los Angeles, CANPI 1104810076
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $101,472 of the $159,459 with a category attached, or 63.6%. Medtronic accounts for 68.7% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2022 at $32,219 and has fallen 81.5% since, to $5,956 in 2025. Among interventional cardiology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 359 payments — averaging $444.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$110K
- Abiomed$28K
- Edwards Lifesciences$4K
- Abbott$3K
- Ancora Heart, Inc.$3K
- Microvention, Inc.$3K
- plus $7K from 17 others
Across 184 payments — averaging $2684.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$299K
- Cathworks, Inc.$120K
- Abbott$64K
- Boston Scientific$11K
What the payments were for
- Consulting fees$13,3728%
- Speaking & faculty fees$101,47264%
- Grants$2250%
- Travel & lodging$28,96818%
- Food & beverage$15,42210%
- Education$10%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 149 | $109,521 |
| Abiomed | 37 | $28,142 |
| Edwards Lifesciences | 41 | $4,472 |
| Abbott | 60 | $3,413 |
| Ancora Heart, Inc. | 11 | $3,340 |
| Microvention, Inc. | 1 | $3,200 |
| Cathworks, Inc. | 1 | $3,000 |
| Boston Scientific | 23 | $2,308 |
| GE HealthCare | 8 | $853 |
| Shockwave Medical, Inc | 6 | $308 |
| Biotronik Inc. | 7 | $167 |
| Impulse Dynamics (USA) Inc. | 1 | $150 |
| Teleflex LLC | 1 | $146 |
| Novartis | 2 | $144 |
| Imperative Care, Inc | 1 | $62 |
| W. L. Gore & Associates, Inc. | 1 | $53 |
| Philips North America LLC | 3 | $42 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $31 |
| Acist Medical Systems, Inc. | 1 | $27 |
| B. Braun Interventional Systems Inc. | 1 | $23 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Cook Medical LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$53,062
- CoreValve Evolut$48,150
- Impella$26,299
- ROADSAVER$3,200
- AccuCinch$3,157
- FFRangio$3,000
- MO.MA ULTRA$1,290
- EXPORT AP$880
- TrailBlazer$630
- APOLLOTM$525
- MitraClip$413
- Portico Transcatheter Aortic HV$383
- EVOQUE$375
- SAPIEN 3 Ultra RESILIA$326
- AVVIGO Guidance System$304
- OPTIMIZER$300
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$192
- GENERAL - THERAPIES$175
- PORTICO$174
- WATCHMAN FLX$169
How this compares
$159,459 in reported general payments places this provider in the 90th percentile of 585 interventional cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 77 | $93,010 |
| EntrestoSacubitril/Valsartan | 48 | $39,820 |
| Repatha SureclickEvolocumab | 41 | $34,257 |
| JardianceEmpagliflozin | 23 | $25,138 |
| XareltoRivaroxaban | 13 | $20,405 |
| Ranolazine ErRanolazine | 22 | $3,122 |
| Atorvastatin Calcium | 144 | $2,075 |
| Metoprolol Succinate | 137 | $2,003 |
| Losartan Potassium | 127 | $1,441 |
| Amlodipine Besylate | 116 | $1,297 |
| Rosuvastatin Calcium | 82 | $1,078 |
| Nitroglycerin | 45 | $1,031 |
| Ezetimibe | 39 | $894 |
| Doxazosin Mesylate | 49 | $772 |
| Bumetanide | 18 | $727 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $144 | $39,82048 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 585 interventional cardiology providers in California.
Other interventional cardiology in Los Angeles
- Evan ZahnLos Angeles$632K
- Steven BursteinLos Angeles$352K
- Jubin JosephLos Angeles$217K
- Ali NsairLos Angeles$162K
- Daniel AsemotaLos Angeles$155K
- Christina EconomidesLos Angeles$150K
- Aakriti GuptaLos Angeles$139K
- Matthew Pricela Jolla$2.3M
- Frederick St GoarMountain View$2.2M
- Saibal KarThousand Oaks$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.